Last reviewed · How we verify
Sodium Chloride 0.9% for Injection, Preservative Free
Sodium Chloride 0.9% for Injection, Preservative Free, is a marketed product developed by Stanford University, with a key composition patent expiring in 2028. The drug's preservative-free formulation offers a significant competitive advantage in maintaining sterility and stability. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Sodium Chloride 0.9% for Injection, Preservative Free |
|---|---|
| Also known as | Saline |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: